earningsconfidence high
Century Therapeutics reports Q1 net loss of $21.6M; cash runway into Q1 2029; CNTY-813 IND on track for 4Q 2026
Century Therapeutics, Inc.
2026-Q1 EPS reported
-$0.11
- Net loss of $21.6M for Q1 2026 vs net income of $76.6M in Q1 2025; R&D $17.1M, G&A $6.6M.
- Cash, cash equivalents and marketable securities $217.0M as of March 31, 2026; runway into Q1 2029.
- CNTY-813 (type 1 diabetes iPSC islet) IND submission on track for 4Q 2026; initial clinical data expected 2H 2027; ADA presentation June 8, 2026.
- CNTY-308 (CD19 CAR-iT) to enter clinic in 2026 pending regulatory clearance; targeting B-cell mediated diseases.
- Completed $135M oversubscribed private placement in January 2026; net cash used in ops $25.3M (down from $34.6M).
item 2.02item 9.01
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.